Filter
Period
Filter by
recent search
Showing: 1 – 05 of 124 Regulated Information
–
13 February 2024
13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as…
–
08 February 2024
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
–
06 February 2024
06 February 2024
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
22 January 2024
22 January 2024
Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
PARIS, FRANCE, 22 January 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today new data to be presented for Cabometyx® (cabozantinib) in combination with immunotherapy across indications at the upcoming American Society of Clinical Oncology Genitourinary Symposium (ASCO GU) taking…
–
08 January 2024
08 January 2024
Ipsen – Half year statement – 2023 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF